Study on the Effectiveness of an Emollient Cream Containing Pre and Postbiotic and Niacinamide 4% in the Treatment of Skin Xerosis and Itching in Oncological Patients Treated with Anti-EGFR

Launched by SOCIETA ITALIANA DI DERMATOLOGIA MEDICA, CHIRURGICA, ESTETICA E DI MALATTIE SESSUALMENTE TRASMESSE · Mar 4, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at the effectiveness of a special cream designed to help with dry skin (called xerosis) and itching in cancer patients who are receiving a specific type of treatment known as anti-EGFR therapy. The cream contains ingredients called prebiotics, postbiotics, and niacinamide, which are thought to help improve skin health. The study is currently recruiting participants aged 18 and older who have been on anti-EGFR therapy for at least three months.

To participate, individuals must be able to provide informed consent and should not have certain skin reactions or conditions that could affect the results. Participants will apply the cream as part of the study and may help researchers learn more about how to relieve skin dryness and discomfort in patients undergoing cancer treatment. This trial is an important step in finding better ways to support patients experiencing these common side effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. patients aged 18 who have been receiving anti-EGFR therapy for more than three months,
• • 2. signature of the informed consent.
• Exclusion Criteria:
• • 1. Patients diagnosed with Grade II papulopustulous skin reaction according to the Common Terminology Criteria for Adverse Event (CTCAE) scale at the time of enrolment;
• • 2. concomitant use of emollients and/or steroidal creams;
• • 3. personal history of xerotic pathologies (e.g. lichen, ichthyosis) and/or itching of n.d.d.;
• • 4. inability to provide informed consent or inability to complete the procedures required for enrollment in the study.